---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018581"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:16:52.627653+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aprea reports Q3 net loss $3.2M; cash $25.4M; ATRN-1051 IND on track for Q4 2023

## Summary
- Net loss of $3.2M ($0.86/sh) vs $4.0M ($2.32/sh) in Q3 2022; operating loss reduced to $3.5M.
- Cash and equivalents $25.4M as of Sep 30, 2023; cash runway through Q4 2024.
- ATRN-119 dose escalation at cohort 4 (350mg); dose expansion enrollment expected Q2 2024.
- ATRN-1051 IND submission planned Q4 2023 with clearance Q1 2024; Phase 1/2a start H1 2024.
- R&D expenses $2.1M (up from $1.1M) due to ATRN-1051 IND studies; G&A down to $1.7M.

## SEC filing metadata
- accession: 0001558370-23-018581
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/0001558370-23-018581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/apre-20231109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018581
- JSON: https://secwatch.observer/filing/0001558370-23-018581.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018581.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported three and nine months ended September 30, 2023 results: net income a net loss of $3.2 million ($0.86 per basic share), EPS ($0.86 per basic share).
  - Period: three and nine months ended September 30, 2023
  - Net income: a net loss of $3.2 million ($0.86 per basic share)
  - EPS: ($0.86 per basic share)
  - Result: reported results
  source text: Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/0001558370-23-018581-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.